Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5138 - Biomarker-driven access to crizotinib in ALK, MET or ROS1 positive (+) malignancies in adults and children: the French national AcSé Program


22 Oct 2018


Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care


Cytotoxic Therapy;  Targeted Therapy

Tumour Site


Gilles Vassal


Annals of Oncology (2018) 29 (suppl_8): viii133-viii148. 10.1093/annonc/mdy279


G. Vassal1, N. Cozic2, R. Houot3, L. Brugières4, T. Aparicio5, J. Blay6, M. Perol6, P. Brice7, E. Meriaux8, B. Geoerger4, M.R. El Bejjani9, S. Moalla9, I. Bièche10, S. Lantuejoul11, C. Mahier Ait Oukhatar12, N. Hoog Labouret13, D. Moro-Sibilot14

Author affiliations

  • 1 Clinical research Department, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 2 Oncostat, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 3 Hematology, Hôpital Pontchaillou, Rennes/FR
  • 4 Department Of Pediatric And Adolescent Oncology, Gustave Roussy Cancer Campus Grand Paris, 94805 - Villejuif/FR
  • 5 Gastroenterology And Digestive Oncology, Hôpital Saint Louis, 75010 - Paris/FR
  • 6 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 7 Hematology And Oncology, Hôpital St. Louis, 75010 - Paris/FR
  • 8 Medical Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 9 Radiology, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 10 Pharmacogenomics Unit, Institut Curie, 75005 - PARIS/FR
  • 11 Department Of Biopathology, Centre Léon Bérard, 69008 - Lyon/FR
  • 12 Research And Development, UNICANCER, 75654 - Paris/FR
  • 13 Biology, Transfert And Innovation Department, Institut National du Cancer, 92100 - Boulogne Billancourt/FR
  • 14 Thoracic Pneumology, Hôpital Michallon, 38043 - Grenoble/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5138


Crizotinib (czb) was registered for ALK+ NSCLC in 2013 and recently for ROS1+ stage IV NSCLC. Czb targets (ALK, MET, ROS1) are also altered (translocation [tlc], amplification [amp], mutation [mut]) in a wide range of malignancies (malg.) in adults and children. To generate high evidenced-based knowledge and to prevent off-label use, the French National Cancer Institute (INCa) launched the AcSé Program: equal access to tumor molecular diagnosis including an exploratory phase II trial.


Biomarker testing was proposed to patients (pts) ≥ 1 year old (yo) with an advanced disease among more than 15 malg. known to harbor a czb target alteration. If not eligible for any other trial, pts may enter one of the 22 cohorts defined by the type of tumor and target. Tumor response was evaluated every 2 months (mo) using RECIST v1.1. The primary endpoint is the objective response rate (ORR) at 2 mo [complete + partial response]. A two-stage Simon design is applied to each cohort.


From 08/2013 to 03/2018, 13179 pts from 186 centers have entered the biomarker program. Tumor alterations found in pts were: ALK tlc, mut, amp in 14/2070, 8/313, 10/1858; MET amp (≥6 copies/diploid genome) in 395/7932 [251/4171 NSCLC, 60/1232 glioblastomas, 28/939 colon, 35/570 esogastric, 7/640 ovarian cancers]; MET mut in 102/2836; ROS1 tlc in 82/4755 [NSCLC, cholangiocarcinoma, inflammatory myofibroblastic tumor (IMT)]. Overall, 237 pts (median age, 57 [1–92]) received czb (adult 250 mg bid; child 280 mg/m² bid).Table: 434P

Positive cohortsPts analyzedCR/PR at 2 moORR % [IC95%]
ALCL ALK tlc241254 [34-75]
NSCLC MET amp ROS1 tlc MET mut25 37 28*7 20 5**28 [10 - 46] 54 [38 - 70] 18 [4 -32]
Esogastric MET amp9333 [7-70]
IMT ALK tlc / ROS1 tlc8338 [9-76]

including 4 pts wIth MET mut on other exon than exon 14


pts with MET mut exon 14 195 grade ≥3 adverse events (AEs) or SAE were reported in 83/237 pts. Grade ≥3 AEs were: ALT increased (6%), neutropenia (5%) and lymphopenia (5%).


Czb displayed a wide antitumor activity in several MET, ALK and ROS1+ malg. Equal and safe access across France to molecular testing and targeted therapies outside their approved indication is feasible.

Clinical trial identification


Legal entity responsible for the study



ARC Foundation Inca Pfizer.

Editorial Acknowledgement


G. Vassal: Travel, accomodations, expenses: BMS. J-Y. Blay: Advisory Board: Roche, Lilly, Ignyta, Deciphera, Novartis, Bayer, BMS; Corporate-sponsored research: Roche, Lilly, Ignyta, Deciphera, Novartis, Bayer, Novartis, GSK, AstraZeneca, MSD; Other substantive relationships: Surveillance committee of Innate Pharma. M. Perol: Advisory board: Pfizer. P. Brice: Advisory board: Takeda France; Corporate-sponsored research: Takeda Millenium, BMS, MSD. D. Moro-Sibilot: Speaker or advisory board: Eli Lilly, MSD, Roche, Novartis, BMS, Astra Zeneca, Takeda, Boehringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.